Clinical trial · no report yet · Phase 3
NCT04821622
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
- NCT04821622 ↗
- Active not recruiting
- Pfizer
- 217 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 83 | |
| YouTube | 75 | |
| Podcasts | 53 | |
| X videos | 6 |
The trial
ClinicalTrials.gov- Official title
- TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Prostate Cancer
- Interventions
- talazoparib plus enzalutamide; Placebo plus enzalutamide
- Arms
- Arm 1 · Experimental
- Arm 2 · Active comparator
- Enrollment
- 599
- Primary outcomes
- radiological Progression-Free Survival
- Sponsor
- Pfizer with Astellas Pharma Inc
- Start
- May 12, 2021
- Primary completion
- Feb 18, 2026
- Results posted
- No
- Registry record
- NCT04821622 · updated Sep 4, 2026
Publications
linked from the registry- Agarwal N, Matsubara N, Azad AA, Saad F, Mateo J, Jiang S, Ye D, Voog E, Shore ND, Cil T, Vulsteke C, Chung HJ, Zschabitz S, Laird AD, Zhang X, Nandoskar P, Chetcuti SF, Wang F, Fizazi K. PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer. N Engl J Med. 2026 Jul 30;395(5):427-439. doi: 10.1056/NEJMoa2604126. Epub 2026 May 30. PubMed 42223064
- Agarwal N, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen HC, Lanzalone S, Niyazov A, Fizazi K. TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Future Oncol. 2024 Mar;20(9):493-505. doi: 10.2217/fon-2023-0526. Epub 2023 Oct 26. PubMed 37882449